AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.30 mg
Number of subjects: 22
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg and 0.30 mg
Number of subjects: 22
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 22
Study 6994771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 22
Study 6994771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31764741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 1 g
Number of subjects: 75
Study 31764741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen 1 g
Number of subjects: 75
Study 27932535 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional multiple-set resistance exercise (TR)
Number of subjects: 14
Study 27932535 — intervention group
Group type: COMPARATOR
Intervention: Circuit resistance exercise (CI)
Number of subjects: 14
Study 27052065 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintubation airway assessment using adult fiberoptic bronchoscope (FOB)
Number of subjects: 84
Study 27052065 — intervention group
Group type: COMPARATOR
Intervention: Blind placement of DLETTs and BBs followed by clinical confirmation by auscultation
Number of subjects: 84
Study 23335452 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 54
Study 23335452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group cognitive treatment (IGCT)
Number of subjects: 54
Study 22801833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed) for 6 months
Number of subjects: 107
Study 22801833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management (nasolacrimal duct massage and topical antibiotics as needed)
Number of subjects: 107
Study 19178748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery ligation
Number of subjects: 0
Study 19178748 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted vaginal hysterectomy
Number of subjects: 0
Study 17550443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment with a 530- to 750-nm filter
Number of subjects: 30
Study 17550443 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 30
Study 15878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants (4-month-olds) responding to color categorization in a target detection task.
Number of subjects: 0
Study 15878166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults responding to color categorization in a target detection task.
Number of subjects: 0
Study 12162603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 19
Study 12162603 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 19
Study 10217341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained release morphine (MST)
Number of subjects: 6
Study 10217341 — intervention group
Group type: COMPARATOR
Intervention: Rectal morphine sulfate suppositories (MSR)
Number of subjects: 6
Study 1346956 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily gentamicin (4 mg/kg/day)
Number of subjects: 20
Study 1346956 — intervention group
Group type: COMPARATOR
Intervention: Twice daily gentamicin (4 mg/kg/day)
Number of subjects: 20
Study 1346956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosage schedules of gentamicin
Number of subjects: 20
Study 6465510 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion + 400 mg cimetidine i.m. 120 min before histamine infusion
Number of subjects: 8
Study 6465510 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg promethazine i.m. 45 min before histamine infusion
Number of subjects: 8
Study 6465510 — intervention group
Group type: COMPARATOR
Intervention: Histamine-induced effects without premedication
Number of subjects: 8
Study 29200001 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage 3 times a week for 6 weeks
Number of subjects: 46
Study 29200001 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 46
Study 29698253 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon alarms
Number of subjects: 20
Study 29698253 — intervention group
Group type: COMPARATOR
Intervention: Standard alarms
Number of subjects: 20
Study 27672108 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib at a maximum tolerated dose (MTD) of 0.8 mg/kg, administered as three weekly intravenous infusions per 28-day cycle.
Number of subjects: 57
Study 25427070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (1 mg/ml) after paring the hyperkeratotic tissue
Number of subjects: 50
Study 25427070 — intervention group
Group type: COMPARATOR
Intervention: Simple paring
Number of subjects: 50
Study 23829408 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours, using the 30° tilt
Number of subjects: 213
Study 23829408 — intervention group
Group type: COMPARATOR
Intervention: Standard care, repositioned every 6 hours, using the 90° lateral rotation
Number of subjects: 213
Study 19880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1040
Study 19880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (α2C wild type)
Number of subjects: 1040
Study 19880803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol (α2C Del carriers)
Number of subjects: 1040
Study 19880803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1040
Study 18945992 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (20 microg/kg per day)
Number of subjects: 2500
Study 18945992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 16640637 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive information about pain during ET (experimental group)
Number of subjects: 437
Study 16640637 — intervention group
Group type: COMPARATOR
Intervention: Informative paragraphs (control groups)
Number of subjects: 437
Study 12634581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 300/75 mg/m2 twice daily (after initial dosing of 230/57.5 mg/m2 or 300/75 mg/m2)
Number of subjects: 100
Study 12634581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 300/75 mg/m2 twice daily
Number of subjects: 100
Study 12634581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 100
Study 11314239 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (100 mg i.m./14 days)
Number of subjects: 60
Study 11314239 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroid treatment (fluticasone or beclomethasone) without clodronate
Number of subjects: 60
Study 9033521 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program in nursing homes
Number of subjects: 1152
Study 9033521 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 1152
Study 8070823 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day plus aspirin and calcium blockers
Number of subjects: 95
Study 8070823 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (aspirin and calcium blockers)
Number of subjects: 95
Study 3554456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ-carbenicillin regimen
Number of subjects: 126
Study 3554456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ (oral)
Number of subjects: 126
Study 3554456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ (intravenous)
Number of subjects: 126
Study 3554456 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ in combination with aminoglycoside or antipseudomonal penicillin
Number of subjects: 126
Study 29280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium curettes (TC)
Number of subjects: 18
Study 29280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel ultrasonic tip (PS)
Number of subjects: 18
Study 29280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air‐polishing powder (EP)
Number of subjects: 18
Study 29280076 — intervention group
Group type: COMPARATOR
Intervention: Rubber cup polishing (CON)
Number of subjects: 18
Study 26492541 — intervention group
Group type: COMPARATOR
Intervention: CIO (Complete Insulin Orders)
Number of subjects: 61
Study 26492541 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH-CIO (NPH plus CIO)
Number of subjects: 61
Study 24356795 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g purified EPA/DHA for 6 weeks
Number of subjects: 34
Study 24356795 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo) for 6 weeks
Number of subjects: 34
Study 22865311 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in smokers with short time to treatment (<3 hours)
Number of subjects: 1572
Study 22865311 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in smokers with short time to treatment (<3 hours)
Number of subjects: 1572
Study 22865311 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in non-smokers with short time to treatment (<3 hours)
Number of subjects: 1572
Study 22865311 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in non-smokers with short time to treatment (<3 hours)
Number of subjects: 1572
Study 22865311 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in patients with >3 hours to treatment
Number of subjects: 1572
Study 22865311 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis in patients with >3 hours to treatment
Number of subjects: 1572
Study 20651010 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity, individualized (HI) treadmill training
Number of subjects: 30
Study 20651010 — intervention group
Group type: COMPARATOR
Intervention: Lower-intensity, generalized (LG) treadmill training
Number of subjects: 30
Study 18759320 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Physical Activity (MPA)
Number of subjects: 255
Study 18759320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity (VPA)
Number of subjects: 255
Study 18759320 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Physical Activity adherence
Number of subjects: 255
Study 18759320 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of adherence between genders
Number of subjects: 255
Study 16444910 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 5 mg/day
Number of subjects: 100
Study 16444910 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 10 mg/day
Number of subjects: 100
Study 16444910 — intervention group
Group type: COMPARATOR
Intervention: Policosanol 5 mg/day
Number of subjects: 100
Study 16444910 — intervention group
Group type: COMPARATOR
Intervention: Policosanol 10 mg/day
Number of subjects: 100
Study 12750868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 IU hGH/kg BW per day
Number of subjects: 15
Study 12750868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10496201 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 6500
Study 10496201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 8929439 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (1 mg/kg IV over 20 min)
Number of subjects: 0
Study 8929439 — intervention group
Group type: COMPARATOR
Intervention: Saline (IV)
Number of subjects: 0
Study 1676246 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 50
Study 1676246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6835985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6835985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30365464 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 349
Study 30365464 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (early initiation trials)
Number of subjects: 349
Study 30365464 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 349
Study 30015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocket stove (intervention)
Number of subjects: 222
Study 30015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed use of intervention and traditional stoves
Number of subjects: 222
Study 30015250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive and mixed stove users
Number of subjects: 222
Study 30015250 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional stoves)
Number of subjects: 222
Study 27271662 — intervention group
Group type: EXPERIMENTAL
Intervention: MWP_CANBol
Number of subjects: 0
Study 27271662 — intervention group
Group type: EXPERIMENTAL
Intervention: CANPBol
Number of subjects: 0
Study 27271662 — intervention group
Group type: COMPARATOR
Intervention: WWB
Number of subjects: 0
Study 25160013 — intervention group
Group type: EXPERIMENTAL
Intervention: GTE2 (2 g/d)
Number of subjects: 30
Study 25160013 — intervention group
Group type: EXPERIMENTAL
Intervention: GTE4 (4 g/d)
Number of subjects: 30
Study 25160013 — intervention group
Group type: EXPERIMENTAL
Intervention: GTE6 (6 g/d)
Number of subjects: 30
Study 23067900 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach (n = 83)
Number of subjects: 160
Study 23067900 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach (n = 77)
Number of subjects: 160
Study 19220616 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention
Number of subjects: 288
Study 19220616 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 288
Study 17261427 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter medications
Number of subjects: 87
Study 17261427 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 87
Study 17261427 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related problems
Number of subjects: 87
Study 15123533 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 42
Study 15123533 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 42
Study 11777497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ziprasidone
Number of subjects: 0
Study 11777497 — intervention group
Group type: EXPERIMENTAL
Intervention: BARS
Number of subjects: 0
Study 11477858 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection combined with chemotherapy (Group A)
Number of subjects: 182
Study 11477858 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Group C)
Number of subjects: 182
Study 11477858 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (Group B)
Number of subjects: 182
Study 8588267 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoxate treatment (1,200 mg/day, 400 mg t.i.d. for 12 weeks)
Number of subjects: 70
Study 8588267 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 70
Study 2523634 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic enoximone therapy (1 and 2 mg/kg)
Number of subjects: 20
Study 2523634 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 20
Study 1094871 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride nebulization
Number of subjects: 19
Study 1094871 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 19
Study 1094871 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol hydrochloride and placebo nebulizations
Number of subjects: 19
Study 31415883 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhoid vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur)
Number of subjects: 20
Study 31415883 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 20
Study 28691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (group A, 35 participants)
Number of subjects: 109
Study 28691557 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (group B, 18 participants)
Number of subjects: 109
Study 28691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (group C, 24 participants)
Number of subjects: 109
Study 26183021 — intervention group
Group type: EXPERIMENTAL
Intervention: TBCT (Traditional Behavioral Couple Therapy)
Number of subjects: 104
Study 26183021 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCT (Integrative Behavioral Couple Therapy)
Number of subjects: 104
Study 26183021 — intervention group
Group type: EXPERIMENTAL
Intervention: TBCT couples
Number of subjects: 104
Study 26183021 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCT couples
Number of subjects: 104
Study 24353022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 or 100 mg
Number of subjects: 378
Study 24353022 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR 5 or 10 mg
Number of subjects: 378
Study 24353022 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 378
Study 24353022 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 378
Study 21462153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 41
Study 21462153 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy alone (Control)
Number of subjects: 41
Study 18272933 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX=60 min cycling at 60% VO(2peak))
Number of subjects: 20
Study 18272933 — intervention group
Group type: COMPARATOR
Intervention: Control (CT=no exercise)
Number of subjects: 20
Study 18272933 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20
Study 18272933 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 20
Study 18272933 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight (NW)
Number of subjects: 20
Study 18272933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (OW)
Number of subjects: 20
Study 16801653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial three-dimensional TOF MRA
Number of subjects: 10
Study 16801653 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity digital subtraction venography (DSV) and thoracic inlet MRI
Number of subjects: 10
Study 14578078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 presentation of the standard duration
Number of subjects: 0
Study 14578078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 presentations of the standard duration
Number of subjects: 0
Study 14578078 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 presentations of the standard duration
Number of subjects: 0
Study 14578078 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of feedback on performance accuracy
Number of subjects: 0
Study 14578078 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of feedback on performance accuracy
Number of subjects: 0
Study 11094583 — intervention group
Group type: EXPERIMENTAL
Intervention: oral clonidine 2 micrograms kg‐1
Number of subjects: 90
Study 11094583 — intervention group
Group type: EXPERIMENTAL
Intervention: oral clonidine 4 micrograms kg‐1
Number of subjects: 90
Study 11094583 — intervention group
Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 90
Study 8982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 468
Study 8982892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 1473445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug, simvastatin
Number of subjects: 321
Study 6628810 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) at three dose levels
Number of subjects: 6
Study 31680600 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine infusion
Number of subjects: 53
Study 31680600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30832708 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPS programme delivered by an internal early teacher
Number of subjects: 80
Study 30832708 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPS programme delivered by an external early teacher
Number of subjects: 80
Study 30832708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29642312 — intervention group
Group type: COMPARATOR
Intervention: Maltitol oral spray
Number of subjects: 81
Study 29642312 — intervention group
Group type: COMPARATOR
Intervention: Xylitol chewing gum
Number of subjects: 81
Study 29642312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 25876529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (DSM 17938) at a dose of 10^8 colony forming units
Number of subjects: 42
Study 25876529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical formulation without live micro-organisms)
Number of subjects: 42
Study 25876529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (DSM 17938)
Number of subjects: 42
Study 25876529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23810881 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1000
Study 23810881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 20162373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), average of ten sessions
Number of subjects: 40
Study 20162373 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40
Study 19597054 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake of 5 to 14.9 g/d
Number of subjects: 26399
Study 19597054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediating factors (lipids, hemoglobin A1c/diabetes, inflammatory/hemostatic factors, blood pressure factors)
Number of subjects: 26399
Study 19597054 — intervention group
Group type: EXPERIMENTAL
Intervention: All mediating factors
Number of subjects: 26399